首页> 外文期刊>Acta biomaterialia >Sustained release of triamcinolone acetonide from an episcleral plaque of multilayered poly-ε-caprolactone matrix
【24h】

Sustained release of triamcinolone acetonide from an episcleral plaque of multilayered poly-ε-caprolactone matrix

机译:从多层聚ε-己内酯基质的巩膜斑块中缓释丙酮酸曲安奈德

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A subtenon injection of triamcinolone acetonide (TA) is a widely used treatment modality for various chorio-retinal diseases. Although it is less invasive than intravitreal injection, it can produce dose-associated ocular complications and has the disadvantages associated with systemic TA exposure. In this study we have developed and evaluated an episcleral film consisting of TA and poly-ε-caprolactone (PCL). The films were prepared by spraying a mixture of PCL in dichloromethane and TA in acetone. The films were produced as 6 mm wide and 12 mm long episcleral plaques. X-ray diffraction demonstrated an even distribution of TA crystals in PCL, although the TA was less crystalized than a native TA control. Fourier transform infrared spectroscopy revealed effective integration of TA within the PCL matrix. An in vitro study of the release of TA from the episcleral plaques showed that TA release rate was only 40-50% that of the equivalent native TA control. An in vivo study demonstrated that the plaques were well tolerated in rabbit eyes with significantly less systemic TA exposure. The episcleral plaques provided therapeutic vitreous TA levels for 3 months, while TA levels in the vitreous were detectable for only 1 month following an equivalent dose by subtenon TA injection. The PCL-TA 30-60 episcleral plaque may be further developed as a better alternative treatment for many chronic vitreo-retinal diseases, providing longer and controlled release and fewer drug-associated complications than those associated with a conventional subtenon injection of TA.
机译:次安定注射曲安奈德(TA)是用于各种脉络膜视网膜疾病的广泛使用的治疗方式。尽管它比玻璃体内注射的侵入性小,但它可以产生与剂量相关的眼部并发症,并且具有与全身性TA暴露相关的缺点。在这项研究中,我们开发并评估了由TA和聚ε-己内酯(PCL)组成的巩膜。通过将PCL的二氯甲烷混合物和TA的丙酮混合物喷雾来制备薄膜。膜被制成6mm宽和12mm长的巩膜斑。 X射线衍射表明TAL在PCL中的分布均匀,尽管TA的结晶度比天然TA对照少。傅里叶变换红外光谱揭示了PCL基质中TA的有效整合。从巩膜斑块中释放TA的体外研究表明,TA释放率仅为同等天然TA对照的40-50%。一项体内研究表明,斑块在兔眼中具有良好的耐受性,全身性TA暴露量明显减少。硬膜斑提供了治疗性玻璃体TA水平,为期3个月,而玻璃体中的TA水平在通过亚剂量的TA注射等效剂量后仅可检测1个月。 PCL-TA 30-60巩膜斑块可能会进一步发展为许多慢性玻璃体视网膜疾病的更好的替代治疗方法,与传统的TA筋膜下注射相比,可提供更长的控制释放时间和更少的药物相关并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号